Swiss Re's $50mn+ extreme mortality issuance under the Vita IV series of transactions is among a number of ILS deals coming to light as the end of the year approaches.
Swiss Re's $50mn+ extreme mortality issuance under the Vita IV series of transactions is among a number of ILS deals coming to light as the end of the year approaches.